168 related articles for article (PubMed ID: 19776211)
1. Estimates of cancer potency of 2,3,7,8-tetrachlorodibenzo(p)dioxin using linear and nonlinear dose-response modeling and toxicokinetics.
Simon T; Aylward LL; Kirman CR; Rowlands JC; Budinsky RA
Toxicol Sci; 2009 Dec; 112(2):490-506. PubMed ID: 19776211
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of benchmark dose methodology for non-cancer continuous-data health effects in animals due to exposures to dioxin (TCDD).
Gaylor DW; Aylward LL
Regul Toxicol Pharmacol; 2004 Aug; 40(1):9-17. PubMed ID: 15265602
[TBL] [Abstract][Full Text] [Related]
3. NTP technical report on the toxicology and carcinogenesis studies of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6) in female Harlan Sprague-Dawley rats (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Apr; (521):4-232. PubMed ID: 16835633
[TBL] [Abstract][Full Text] [Related]
4. Estimates of cancer potency of 2,3,4,7,8-pentachlorodibenzofuran using both nonlinear and linear approaches.
Simon T; Kirman CR; Aylward LL; Budinsky RA; Rowlands JC; Long TF
Toxicol Sci; 2008 Dec; 106(2):519-37. PubMed ID: 18723826
[TBL] [Abstract][Full Text] [Related]
5. Toxicology and carcinogenesis studies of a mixture of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Cas No. 1746-01-6), 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) (Cas No. 57117-31-4), and 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (Cas No. 57465-28-8) in female Harlan Sprague-Dawley rats (gavage studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Sep; (526):1-180. PubMed ID: 17342195
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Integration of Mode of Action Information in Dose-Response Modeling and POD Estimation for Nonmutagenic Carcinogens: A Case Study of TCDD.
Chen Q; Zhou Y; Ji C; Klaunig JE; Shao K
Environ Health Perspect; 2023 Dec; 131(12):127022. PubMed ID: 38157272
[TBL] [Abstract][Full Text] [Related]
7. Toxicology and carcinogenesis studies of 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) (Cas No. 57117-31-4) in female Harlan Sprague-Dawley rats (gavage studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Sep; (525):1-198. PubMed ID: 17160103
[TBL] [Abstract][Full Text] [Related]
8. NTP technical report on the toxicology and carcinogenesis studies of 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) (CAS No. 35065-27-1) in female Harlan Sprague-Dawley rats (Gavage studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 May; (529):4-168. PubMed ID: 16835634
[TBL] [Abstract][Full Text] [Related]
9. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
[TBL] [Abstract][Full Text] [Related]
10. Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose.
Gaylor DW; Swirsky Gold L
Regul Toxicol Pharmacol; 1998 Dec; 28(3):222-5. PubMed ID: 10049793
[TBL] [Abstract][Full Text] [Related]
11. Use of a toxicokinetic model in the analysis of cancer mortality in relation to the estimated absorbed dose of dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin, TCDD).
Salvan A; Thomaseth K; Bortot P; Sartori N
Sci Total Environ; 2001 Jul; 274(1-3):21-35. PubMed ID: 11453298
[TBL] [Abstract][Full Text] [Related]
12. Concentration-dependent TCDD elimination kinetics in humans: toxicokinetic modeling for moderately to highly exposed adults from Seveso, Italy, and Vienna, Austria, and impact on dose estimates for the NIOSH cohort.
Aylward LL; Brunet RC; Carrier G; Hays SM; Cushing CA; Needham LL; Patterson DG; Gerthoux PM; Brambilla P; Mocarelli P
J Expo Anal Environ Epidemiol; 2005 Jan; 15(1):51-65. PubMed ID: 15083163
[TBL] [Abstract][Full Text] [Related]
13. Oral and dermal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces cutaneous papillomas and squamous cell carcinomas in female hemizygous Tg.AC transgenic mice.
Wyde ME; Braen AP; Hejtmancik M; Johnson JD; Toft JD; Blake JC; Cooper SD; Mahler J; Vallant M; Bucher JR; Walker NJ
Toxicol Sci; 2004 Nov; 82(1):34-45. PubMed ID: 15282402
[TBL] [Abstract][Full Text] [Related]
14. Consideration of non-linear, non-threshold and threshold approaches for assessing the carcinogenicity of oral exposure to hexavalent chromium.
Haney J
Regul Toxicol Pharmacol; 2015 Dec; 73(3):834-52. PubMed ID: 26493004
[TBL] [Abstract][Full Text] [Related]
15. Risk assessment of 2,3,7,8-TCDD using a biologically based cancer model: a reevaluation of the Kociba et al. bioassay using 1978 and 1990 histopathology criteria.
Paustenbach DJ; Layard MW; Wenning RJ; Keenan RE
J Toxicol Environ Health; 1991 Sep; 34(1):11-26. PubMed ID: 1653856
[TBL] [Abstract][Full Text] [Related]
16. Comparison of PBTK model and biomarker based estimates of the internal dosimetry of acrylamide.
DeWoskin RS; Sweeney LM; Teeguarden JG; Sams R; Vandenberg J
Food Chem Toxicol; 2013 Aug; 58():506-21. PubMed ID: 23707562
[TBL] [Abstract][Full Text] [Related]
17. Basis for a proposed reference dose (RfD) for dioxin of 1-10 pg/kg-day: a weight of evidence evaluation of the human and animal studies.
Greene JF; Hays S; Paustenbach D
J Toxicol Environ Health B Crit Rev; 2003; 6(2):115-59. PubMed ID: 12554432
[TBL] [Abstract][Full Text] [Related]
18. Pathology reevaluation of the Kociba et al. (1978) bioassay of 2,3,7,8-TCDD: implications for risk assessment.
Keenan RE; Paustenbach DJ; Wenning RJ; Parsons AH
J Toxicol Environ Health; 1991 Nov; 34(3):279-96. PubMed ID: 1942119
[TBL] [Abstract][Full Text] [Related]
19. Toxicology and carcinogenesis studies of a binary mixture of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (Cas No. 57465-28-8) and 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) (CAS No. 35065-27-1) in female Harlan Sprague-Dawley rats (gavage studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Aug; (530):1-258. PubMed ID: 17160104
[TBL] [Abstract][Full Text] [Related]
20. Mode of action and dose-response framework analysis for receptor-mediated toxicity: The aryl hydrocarbon receptor as a case study.
Budinsky RA; Schrenk D; Simon T; Van den Berg M; Reichard JF; Silkworth JB; Aylward LL; Brix A; Gasiewicz T; Kaminski N; Perdew G; Starr TB; Walker NJ; Rowlands JC
Crit Rev Toxicol; 2014 Jan; 44(1):83-119. PubMed ID: 24245878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
